Trusted Resources: News & Meetings
Latest announcements and gatherings
Experimental MPS 1 Therapy Shows Biomarker Activity, Improved Function
REGENXBIO presented results from its ongoing Phase I/II trial of RGX-111, an investigational one-time gene therapy for people with Mucopolysaccharidosis Type I (MPS I). The data, presented at the 18th annual WORLDSymposium, represented six patients diagnosed with severe MPS I who were treated with RGX-111.
Mucopolysaccharidosis Type I is a rare, genetic condition that can affect many parts of the body. The condition stems from a mutation in the IDUA gene which provides instructions for producing an enzyme that is involved in the breakdown of large sugar molecules. In people with MPS I, the gene reduces or completely eliminates the enzymes needed for the breakdown of large sugar molecules, leading to the accumulation of these molecules in cells called lysosomes, whose function is to digest and recycle molecules. The lysosomes become enlarged, causing significant issues in multiple organs including decline in central nervous system (CNS) functioning.
BookmarkRelated Content
-
Sanfilippo Syndrome (MPS III)https://www.onempsvoice.com/wp-content/u...
-
Stem Cell Transplant for Bridgnorth Boy With Rare ConditionTwenty-two-month-old Gunner, from Bridgn...
-
Intracerebral Gene Therapy in Four Children With Sanfilippo B Syndrome: 5.5-Year Follow-Up ResultsWe report the safety (primary endpoint) ...
-
Macular Changes in a Mucopolysaccharidosis Type I Patient With Earlier Systemic TherapiesTo describe retinal findings in a patien...
-
The Youngest Pair of Siblings With Mucopolysaccharidosis Type IVA to Receive Enzyme Replacement Therapy to Date: A C...Mucopolysaccharidosis type IVA (OMIM 253...
-
The MPS I-H Diagnostic Journeyhttps://www.youtube.com/watch?v=jSq5tQD4...
-
Combined Aortic and Mitral Valve Stenosis in Mucopolysaccharidosis Syndrome Type I-S: A Report of a Rare CaseMucopolysaccharidosis (MPS) syndrome is ...
Powered by
